

PHARMACEUTICAL 2023



2seventy bio Inc. Rank 250 of 446







PHARMACEUTICAL 2023



2seventy bio Inc. Rank 250 of 446

The relative strengths and weaknesses of 2seventy bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of 2seventy bio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 77% points. The greatest weakness of 2seventy bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 12% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	300,882
Cost of Goods Sold	1,726
Intangible Assets	19,358
Liabilities, Current	79,794
Liabilities, Non-Current	266,405
Other Assets	280,690
Other Compr. Net Income	-2,165
Other Expenses	24,725
Other Liabilities	0
Other Net Income	8,987
Other Revenues	91,496
Property and Equipment	55,735
Research and Development	248,735
Selling, General and Administrative Expense	79,450

Output Variable	Value in 1000 USD
Assets	656,665
Liabilities	346,199
Expenses	354,636
Revenues	91,496
Stockholders Equity	310,466
Net Income	-254,153
Comprehensive Net Income	-255,236
Economic Capital Ratio	56%

